PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

• Status: Terminated
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical investigation of the potential role of PET perfusion imaging in management of renal carcinoma, and potentially other cancers.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indiana University; James Fletcher
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• Ability to understand and willingness to sign a witnessed, informed consent and authorization for the release of health information.

• Patients with a diagnosis of relapsed Stage IV renal cell cancer that are medically unresponsive to prior treatment or surgically unresectable and with metastases that fall within the PET/CT field-of-view that can include the heart.

• Being considered for systemic therapy with Sunitinib

Exclusion Criteria:

• Women who are pregnant, breast-feeding, or of childbearing potential and not using birth control

• Having no telephone or a reliable way in which study personal can contact them

• Subjects who are claustrophobic and cannot tolerate imaging procedures

• Subjects who weigh > 350 lb. (upper weight limit of scanner beds)